Literature DB >> 12601008

Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity.

Giuseppina Blanca1, Fausto Baldanti, Stefania Paolucci, Alexander Yu Skoblov, Lyubov Victorova, Ulrich Hübscher, Giuseppe Gerna, Silvio Spadari, Giovanni Maga.   

Abstract

Recombinant HIV-1 reverse transcriptase (RT) carrying non-nucleoside inhibitors (NNRTIs) resistance mutation at codon 181 showed reduced incorporation and high efficiency of phosphorolytic removal of stavudine, a nucleoside RT inhibitor. These results reveal a new mechanism for cross-resistance between different classes of HIV-1 RT inhibitors.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12601008     DOI： 10.1074/jbc.C300022200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  8 in total

1.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.

Authors:  Stefania Paolucci; Fausto Baldanti; Giovanni Maga; Reynel Cancio; Maurizio Zazzi; Maurizio Zavattoni; Antonella Chiesa; Silvio Spadari; Giuseppe Gerna
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  Soumi Gupta; Signe Fransen; Ellen E Paxinos; Eric Stawiski; Wei Huang; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

5.  HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate.

Authors:  Giovanni Maga; Marco Radi; Marie-Aline Gerard; Maurizio Botta; Eric Ennifar
Journal:  Viruses       Date:  2010-03-30       Impact factor: 5.818

6.  N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Authors:  Soo-Huey Yap; Chih-Wei Sheen; Jonathan Fahey; Mark Zanin; David Tyssen; Viviane Dias Lima; Brian Wynhoven; Michael Kuiper; Nicolas Sluis-Cremer; P Richard Harrigan; Gilda Tachedjian
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

7.  Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.

Authors:  Marleen C D G Huigen; Petronella M van Ham; Loek de Graaf; Ron M Kagan; Charles A B Boucher; Monique Nijhuis
Journal:  Retrovirology       Date:  2008-02-13       Impact factor: 4.602

8.  Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.

Authors:  Wei Guo; Jingwan Han; Daomin Zhuang; Siyang Liu; Yongjian Liu; Lin Li; Hanping Li; Zuoyi Bao; Fujiang Wang; Jingyun Li
Journal:  Virol J       Date:  2015-11-14       Impact factor: 4.099
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.